Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting
April 08, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of...
Inozyme Pharma Expands its Scientific Advisory Board
April 01, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization,...
Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights
March 25, 2021 06:00 ET
|
Inozyme Pharma Inc.
– Received Orphan Drug Designation by the U.S. Food and Drug Administration for INZ-701 for treatment of ABCC6 deficiency – – Expect to initiate Phase 1/2 trials of INZ-701 for ENPP1 deficiency in...
The Balancing Act® on Lifetime to Feature ENPP1 Deficiency
March 11, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization,...
Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer
February 04, 2021 06:00 ET
|
Inozyme Pharma Inc.
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal...
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
January 04, 2021 06:00 ET
|
Inozyme Pharma Inc.
– U.S. Food and Drug Administration cleared Investigational New Drug Application – – United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application – –...
Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
November 12, 2020 06:00 ET
|
Inozyme Pharma Inc.
– Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency – – Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment...
Inozyme Pharma Appoints Kevin B. Johnson, Ph.D., MBA, as Senior Vice President, Regulatory Affairs
November 09, 2020 06:00 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal...
Inozyme Pharma Appoints Yves Sabbagh, Ph.D., as Senior Vice President and Chief Scientific Officer
October 13, 2020 06:00 ET
|
Inozyme Pharma Inc.
– Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs – – Company Announces Retirement of David Thompson, Ph.D. – –...
Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights
September 03, 2020 16:05 ET
|
Inozyme Pharma Inc.
Upsized IPO in July 2020 raised $128.8 million in gross proceeds Submitted IND for INZ-701 for the treatment of ENPP1 deficiency; currently on FDA clinical hold pending completion of ongoing GLP...